Boston Scientific Corporation (BSX) Earnings Call Transcripts

Boston Scientific Corporation's Latest Earnings Call - Q2 FY2026

In Q2 2026, Boston Scientific reported organic sales growth of 7%, surpassing the guidance of 5% to 7%. Adjusted EPS of $0.86 exceeded the high end of guidance ($0.82 to $0.84), marking a 15% increase year-over-year. However, management revised full-year guidance down to organic revenue growth of 5% to 6% and adjusted EPS of $3.28 to $3.32, citing unexpected market pressures in the WATCHMAN and electrophysiology segments as primary drivers of this change.

Reported metrics

Guidance from management

Management expects full-year 2026 organic revenue growth of 5% to 6% and adjusted EPS of $3.28 to $3.32, reflecting a downward revision due to market pressures.

What management said

I think the 7% to 8% call for the WAMGR is, I think, the appropriate number. In terms of PFA leadership, we have it now -- we have lost some share in the U.S. We continue to do extremely well in Europe and Asia Pac, where the PFA penetration is not quite as high. And we've seen all the competitive launches there. But we do continue to expect some competitive launches will impact performance in second half '26, which ...

Thanks for joining us today. We appreciate your interest in Boston Scientific. If we were unable to get to your question or you have any additional follow-ups, please don't hesitate to reach out to the Investor Relations team. Before you disconnect, Drew will give you all of the pertinent details for the replay. Thank you, everyone.

What analysts pressed on

Analysts expressed concerns regarding the downward revisions in guidance, particularly around the WATCHMAN and electrophysiology segments. There were also inquiries about the potential impact of new competition and the effectiveness of management's strategies to address these challenges.

Main topics on the call

• Revenue Growth Performance — Boston Scientific's Q2 organic sales grew 7%, exceeding the guidance range of 5% to 7%. CEO Mike Mahoney stated, "Total company organic sales grew 7% versus our guide of 5% to 7%".
• Earnings Beat — The company reported adjusted EPS of $0.86, beating the guidance of $0.82 to $0.84. This 15% growth was attributed to favorable tax results, as noted by Mahoney: "driven primarily by some favorable tax results".
• Guidance Revision — Management updated full-year guidance to organic revenue growth of 5% to 6% and adjusted EPS of $3.28 to $3.32, down from previous expectations. Mahoney remarked, "This update today is not the outcome we planned or what ...
• WATCHMAN Market Challenges — The WATCHMAN segment is facing significant headwinds, with expected declines in growth due to clinical evidence impacting referral patterns. Mahoney indicated, "The overall LAAC market slowdown is driven by two main fact...

Read the full Boston Scientific Corporation transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 83 Boston Scientific Corporation earnings call transcripts on record, spanning January 14, 2020 to July 29, 2026. Based on this history, Boston Scientific Corporation reports quarterly. The most recent call on file is dated July 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BSX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

83

First call

January 14, 2020

Most recent

July 29, 2026

Reporting cadence

quarterly